Literature DB >> 3921079

Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

N Willmott, J Cummings, J F Stuart, A T Florence.   

Abstract

Adriamycin-loaded bovine albumin microspheres have been prepared by a technique that allows preparation and administration to animals on the same day. Criteria adopted for injection were that microspheres should be stable and of a size such as to become trapped in capillary beds. These conditions were fulfilled by preparing microspheres using glutaraldehyde concentrations greater than 0.5 per cent and the appropriate combination of stirring speed and continuous phase viscosity. After systemic administration rats were sacrificed at intervals and major visceral organs examined for entrapped microspheres and serum for released drug. Microspheres sieved out in the first capillary bed encountered, the lung, then following biodegradation they disappeared at a rate dependent on the amount of cross-linking agent used in their preparation. In contrast to bolus injection, serum drug levels after microsphere administration indicated an initial rapid release followed by a more protracted phase lasting at least 24 h. This latter observation is consistent with drug release during biodegradation of carrier.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921079     DOI: 10.1002/bdd.2510060111

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  14 in total

1.  Immobilization of active urokinase on albumin microspheres: use of a chemical dehydrant and process monitoring.

Authors:  K Bhargava; H Y Ando
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

2.  (D, L) polylactide microspheres as embolic agent. A preliminary study.

Authors:  P Flandroy; C Grandfils; J Collignon; A Thibaut; N Nihant; S Barbette; R Jerome; P Teyssie
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  In vitro release profile of mitomycin C from albumin microspheres: extrapolation from macrospheres to microspheres.

Authors:  H Natsume; K Sugibayashi; Y Morimoto
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

4.  Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles.

Authors:  C Verdun; F Brasseur; H Vranckx; P Couvreur; M Roland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats.

Authors:  Hilliard L Kutscher; Piyun Chao; Manjeet Deshmukh; Yashveer Singh; Peidi Hu; Laurie B Joseph; David C Reimer; Stanley Stein; Debra L Laskin; Patrick J Sinko
Journal:  J Control Release       Date:  2010-01-05       Impact factor: 9.776

6.  Passive targeting and lung tolerability of enoxaparin microspheres for a sustained antithrombotic activity in rats.

Authors:  Shaimaa S Ibrahim; Rihab Osman; Nahed D Mortada; Ahmed-Shawky Geneidy; Gehanne A S Awad
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Willmott; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

8.  Arteriovenous shunting in patients with colorectal liver metastases.

Authors:  J A Goldberg; J A Thomson; G McCurrach; J H Anderson; N Willmott; R G Bessent; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

9.  Is there a relationship between regional microsphere distribution and hepatic arterial blood flow?

Authors:  J H Anderson; W J Angerson; N Willmott; D J Kerr; C S McArdle; T G Cooke
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

10.  The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour.

Authors:  J A Goldberg; T Murray; D J Kerr; N Willmott; R G Bessent; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.